Literature DB >> 29423012

CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.

Ke Cao1, Minhuan Li2, Ji Miao1, Xiaofeng Lu1, Xing Kang1, Hao Zhu3, Shangce Du1, Xue Li1, Qian Zhang1, Wenxian Guan1, Ying Dong4, Xuefeng Xia1.   

Abstract

Accumulating evidence indicates that long noncoding RNAs (lncRNAs) are involved in diseases such as cancer. However, little is known about the role of lncRNAs in gastrointestinal stromal tumors (GIST). In the present study, we explored the biological function of the lncRNA coiled-coil domain-containing 26 (CCDC26) in imatinib resistance of GIST. We found that human GIST-882 cells with lower CCDC26 expression were less sensitive to imatinib compared with GIST-T1 cells with higher CCDC26 expression. CCDC26 expression decreased in a time-dependent manner in the presence of imatinib. Moreover, small interfering RNA (siRNA) knockdown of CCDC26 increased GIST cell sensitivity to imatinib. The RNA pull-down experiment showed that CCDC26 can interact with c-KIT and that CCDC26 knockdown can upregulate c-KIT expression. We also found that inhibiting c-KIT induced resistance to imatinib. Lastly, we proved that inhibiting c-KIT can reverse CCDC26 knockdown-mediated imatinib resistance in GIST. We suggest that CCDC26 knockdown can induce imatinib resistance in GIST cells by downregulating c-KIT expression. Our results provide a novel insight into imatinib resistance in GIST.

Entities:  

Keywords:  CCDC26; GIST; Long noncoding RNA; c-KIT; chemoresistance

Year:  2018        PMID: 29423012      PMCID: PMC5801365     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  41 in total

Review 1.  LncRNA: a link between RNA and cancer.

Authors:  Guodong Yang; Xiaozhao Lu; Lijun Yuan
Journal:  Biochim Biophys Acta       Date:  2014-08-23

2.  Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer.

Authors:  Ling Li; Lei Zhang; Yan Zhang; Fang Zhou
Journal:  Biomed Pharmacother       Date:  2015-04-14       Impact factor: 6.529

Review 3.  lncRNAs: linking RNA to chromatin.

Authors:  John L Rinn
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-08-01       Impact factor: 10.005

4.  Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach.

Authors:  Patrick Schöffski; Agnieszka Wozniak; Oliver Schöffski; Liesbet van Eycken; Maria Debiec-Rychter
Journal:  Oncol Res Treat       Date:  2016-11-18       Impact factor: 2.825

Review 5.  Basic biology and therapeutic implications of lncRNA.

Authors:  O Khorkova; J Hsiao; C Wahlestedt
Journal:  Adv Drug Deliv Rev       Date:  2015-05-27       Impact factor: 15.470

6.  LncRNA expression profile reveals the potential role of lncRNAs in gastric carcinogenesis.

Authors:  Wei Gu; Tian Gao; Ying Sun; Xiong Zheng; Ji Wang; Jin Ma; Xiaoying Hu; Jian Li; Meijie Hu
Journal:  Cancer Biomark       Date:  2015       Impact factor: 4.388

7.  High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.

Authors:  Hong-Tu Zheng; De-Bing Shi; Yu-Wei Wang; Xin-Xiang Li; Ye Xu; Pratik Tripathi; Wei-Lie Gu; Guo-Xiang Cai; San-Jun Cai
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Min-Hee Ryu; Changhoon Yoo; Baek-Yeol Ryoo; Hyun Jin Kim; Jong Jin Lee; Byung-Ho Nam; Nikhil Ramaiya; Jyothi Jagannathan; George D Demetri
Journal:  Lancet Oncol       Date:  2013-10-18       Impact factor: 41.316

9.  Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer.

Authors:  Debing Shi; Hongtu Zheng; Changhua Zhuo; Junjie Peng; Dawei Li; Ye Xu; Xinxiang Li; Guoxiang Cai; Sanjun Cai
Journal:  Med Oncol       Date:  2014-06-08       Impact factor: 3.064

Review 10.  Imatinib treatment for gastrointestinal stromal tumour (GIST).

Authors:  Lisandro F Lopes; Carlos E Bacchi
Journal:  J Cell Mol Med       Date:  2009-11-28       Impact factor: 5.310

View more
  6 in total

1.  Long Noncoding RNA CCDC26 Promotes Thyroid Cancer Malignant Progression via miR-422a/EZH2/Sirt6 Axis.

Authors:  Xiao Ma; Yanyan Li; Yuntao Song; Guohui Xu
Journal:  Onco Targets Ther       Date:  2021-05-11       Impact factor: 4.147

2.  Identification of long intergenic non-coding RNAs (lincRNAs) deregulated in gastrointestinal stromal tumors (GISTs).

Authors:  Ugne Gyvyte; Juozas Kupcinskas; Simonas Juzenas; Ruta Inciuraite; Lina Poskiene; Violeta Salteniene; Alexander Link; Matteo Fassan; Andre Franke; Limas Kupcinskas; Jurgita Skieceviciene
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

Review 3.  Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor.

Authors:  Jiehan Li; Shuning Guo; Zhenqiang Sun; Yang Fu
Journal:  Front Cell Dev Biol       Date:  2022-01-31

Review 4.  Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors.

Authors:  Xiangchen Hu; Zhe Wang; Peng Su; Qiqi Zhang; Youwei Kou
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

5.  lncRNA polymorphism affects the prognosis of gastric cancer.

Authors:  Yanping Lyu; Shuangfeng Yang; Xuejie Lyu; Yuan-Liang Wang; Shumi Ji; Shuling Kang; Yu Jiang; Jianjun Xiang; Chenzhou He; Peixin Li; Baoying Liu; Chuancheng Wu
Journal:  World J Surg Oncol       Date:  2022-08-31       Impact factor: 3.253

Review 6.  Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors.

Authors:  Azadeh Amirnasr; Stefan Sleijfer; Erik A C Wiemer
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.